The financials
Guardant Health, Inc. by the numbers
Guardant Health, Inc. (GH) reported revenue of $335M in Q2 2026 (quarter ended June 30, 2026), up 44% from the same quarter a year earlier. That came with a gross margin of 65% and net loss of $120M. For the full year FY2025, revenue was $982M (+33% year on year) and net income −$416M. Its largest region in 2026-Q1 was US at $285M, 94% of the disclosed total, just ahead of Non Us at 5.6%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $335M | $232M | +44% |
| Gross profit | $219M | $151M | +45% |
| Operating income | −$129M | −$106M | n/a |
| Net income | −$120M | −$100M | n/a |
| Diluted EPS | −$0.90 | −$0.80 | n/a |
| Geographic | Revenue | Share |
|---|---|---|
| US | $285M | 94% |
| Non Us | $17M | 5.6% |
Business Segments
Revenue split by geographic segment, from SEC XBRL filings.
Latest period: Q1 2026Total $301.7M (+14%)
Non Us grew +73% year on yearUS +47% year on year
Segment Latestquarter on quarteryear on year
- US$284.6M$284.6MQoQ +14%year on year +47%+14%+47%
- Non Us$17.0M$17.0MQoQ +8.1%year on year +73%+8.1%+73%
Diagnostics & Research
Ranks #2 of 29 by Smart Score